Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

European pharma stocks fell after President Trump [wrote to 17 companies]( ...

At their peak last year, one share in the company Novo Nordisk cost $142; now, they can be bought for under $50.

European stocks hit a 4-week low on Friday at the end of a busy week as investors worried about the impact of fresh US levies ...

The U.S. will raise tariffs on scores of nations, effective at 12:01 a.m. on Aug. 7, according to an executive order Trump signed on Thursday. When the action is taken, the result will be ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out ...

President Donald Trump said his administration would “deploy every tool” to get drug prices reduced from large pharmaceutical ...

Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...